Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Erlotinib (Primary) ; Temsirolimus (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 19 Dec 2013 Planned end date changed from 1 Jan 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 11 Jun 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.